Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have been given a consensus rating of “Moderate Buy” by the thirteen research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $10.6667.

Several brokerages have recently issued reports on TSHA. The Goldman Sachs Group set a $11.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, December 4th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $13.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday. Citizens Jmp lifted their target price on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “market outperform” rating in a report on Wednesday, November 5th. Citigroup restated an “outperform” rating on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.00 price objective on shares of Taysha Gene Therapies in a research report on Friday, November 14th.

Insider Activity at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 260,047 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $4.51, for a total transaction of $1,172,811.97. Following the completion of the transaction, the insider directly owned 1,006,439 shares of the company’s stock, valued at $4,539,039.89. The trade was a 20.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 3.78% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of large investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC lifted its holdings in shares of Taysha Gene Therapies by 2,271.8% during the 4th quarter. SG Americas Securities LLC now owns 781,474 shares of the company’s stock valued at $4,298,000 after buying an additional 748,525 shares during the period. JPMorgan Chase & Co. increased its position in Taysha Gene Therapies by 33.1% during the third quarter. JPMorgan Chase & Co. now owns 296,244 shares of the company’s stock valued at $969,000 after acquiring an additional 73,595 shares during the last quarter. CIBC Bancorp USA Inc. bought a new position in Taysha Gene Therapies in the third quarter valued at about $74,000. Sender Co & Partners Inc. purchased a new position in Taysha Gene Therapies in the third quarter worth about $89,000. Finally, Vestal Point Capital LP grew its stake in shares of Taysha Gene Therapies by 83.3% during the 3rd quarter. Vestal Point Capital LP now owns 5,500,000 shares of the company’s stock valued at $17,985,000 after purchasing an additional 2,500,000 shares during the period. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Trading Down 3.1%

Taysha Gene Therapies stock opened at $4.98 on Monday. Taysha Gene Therapies has a 12 month low of $1.05 and a 12 month high of $6.02. The company has a market capitalization of $1.36 billion, a price-to-earnings ratio of -15.09 and a beta of 1.02. The business’s fifty day simple moving average is $4.93 and its two-hundred day simple moving average is $3.86. The company has a current ratio of 10.48, a quick ratio of 10.48 and a debt-to-equity ratio of 0.23.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. As a group, equities analysts predict that Taysha Gene Therapies will post -0.35 earnings per share for the current fiscal year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.